Q. Which organization approved the 2nd Living drug, Qartemi, for treating blood cancer?
Answer: Central Drugs Standard Control Organization (CDSCO)
Notes: The Central Drugs Standard Control Organisation (CDSCO) has approved Qartemi, a second "living drug," which is a Chimeric Antigen Receptor (CAR) T-cell therapy designed to treat blood cancer. "Living drugs" involve modifying a patient's cells and reintroducing them into the body. CAR T-cell therapy is an innovative immunotherapy where T-cells are genetically engineered to target cancer cells. T-cells are extracted from the patient’s blood, modified in the lab by adding a gene for a man-made receptor (CAR), which helps T-cells recognize cancer cells. Modified CAR-T cells are then reintroduced to kill cancer cells.

This question is part of Current Affairs Daily 20 MCQs Series Course on GKToday Android app.